The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19.
Novel Coronavirus (COVID-19) News
Below are links to AHA Today stories on novel coronavirus (COVID-19). For all coronavirus resources and news updates, visit our COVID-19 page.
Latest
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced.
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National Institutes of Health announced.
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-home test to successfully complete traditional premarket review.
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23 flu season, defined as receiving a bivalent booster dose or completing a primary series in the previous two months, and fewer than half of nursing home workers had received a flu vaccine, the Centers for Disease Control and Prevention reported Nov. 9.
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral medications as they transition from federal to commercial distribution, beginning Nov. 1.
The Food and Drug Administration recently extended to 30 months the shelf life for certain lots of Gohibic (vilobelimab), authorized for emergency use to treat COVID-19 in certain hospitalized adults.
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response yesterday awarded $600 million for 12 domestic COVID-19 test manufacturers to expand capacity.
AHA is providing its latest social media toolkit to help hospitals encourage vaccination against COVID-19.
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list price for a new commercialized product could not exceed the retail price in comparable markets globally, HHS said.